Xin Lang Zheng Quan·2025-09-14 12:32Core Viewpoint - Zhejiang Zuoli Pharmaceutical Co., Ltd. recently hosted an investor research event, providing an opportunity for investors to gain insights into the company's operations [1]. Group 1: Research Activity Details - The investor relations activity was a site visit held on September 12, 2025, from 10:00 to 11:00 and 15:30 to 17:00, at the company's conference room [2]. - Participating institutions included CITIC Securities, Hunan Huizhi Rongda, Zhiyuan Capital, among 16 others, with the company represented by Secretary of the Board, Ms. Wu Ying [2]. Group 2: Key Insights from the Research - The collection rhythm for Wuling capsules shows that there are still six provinces not included in the collection, with ongoing renewal work for traditional Chinese medicine collections in Guangdong and the Beijing-Tianjin-Hebei "3+N" alliance expected to be completed this year [3]. - The company is leveraging its collection status to enhance market expansion, focusing on hospitals and grassroots markets to increase market share and strengthen competitiveness [3]. - In the first half of 2025, sales revenue from traditional Chinese medicine formula granules grew by 56.60% year-on-year, leading to an increase in accounts receivable due to longer payment terms compared to general commercial companies [3]. - The company plans to improve accounts receivable management to enhance cash flow stability [3]. - Linglianhua granules, as a unique product in the Wuling series, transitioned to OTC sales last year, targeting health-conscious menopausal women through internet marketing and partnerships with major e-commerce platforms [3]. - The company is actively conducting clinical research to explore different indications and build academic evidence for this product [3]. - The company is seeking acquisition opportunities in advantageous fields such as neurology and psychiatry, focusing on targets that can create synergies with existing products and resources [3]. - After the expansion of the digital workshop for medicinal fungi fermentation, the total production capacity for Wuling mushroom powder will reach 900 tons per year, supporting approximately 2.5 billion yuan in output value [3]. - The digital workshop for solid pharmaceutical preparations is expected to be operational by the end of the year, meeting related demand [3]. - The high sales proportion in the East China region is attributed to the concentration of traditional Chinese medicine sales in Zhejiang Province, benefiting from early channel layout and deep penetration in the economically developed region [3]. - Sales in provinces such as Guangdong, Henan, Beijing, and Hebei are rapidly increasing as the company expands its market beyond Zhejiang and participates in collections [3].